Explore how proteomics transforms pharmaceutical R&D, from drug discovery to biomarker qualification and clinical development.
The first-in-human phase 1/2 study of TSN1611, a highly selective KRAS G12D inhibitor, in patients with advanced solid tumors. Seizure-related homolog 6 (SEZ6) expression and ctDNA methylation ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results